tiprankstipranks
Advertisement
Advertisement

KPTI Stock Latest News

Karyopharm price target lowered to $8 from $12 at Piper Sandler
The FlyKaryopharm price target lowered to $8 from $12 at Piper Sandler
2d ago
KPTI
Karyopharm Strengthens Liquidity With New Equity Financing
PremiumCompany Announcements
Karyopharm Strengthens Liquidity With New Equity Financing
5d ago
8K
KPTI
Karyopharm price target lowered to $15 from $21 at Baird
PremiumThe Fly
Karyopharm price target lowered to $15 from $21 at Baird
7d ago
KPTI
Karyopharm price target lowered to $8 from $15 at H.C. Wainwright
PremiumThe Fly
Karyopharm price target lowered to $8 from $15 at H.C. Wainwright
7d ago
KPTI
Karyopharm Announces Financing and Positive SENTRY Trial Results
PremiumCompany Announcements
Karyopharm Announces Financing and Positive SENTRY Trial Results
8d ago
8K
KPTI
Karyopharm up 23% after Phase 3 SENTRY trial meets first co-primary endpoint
PremiumThe FlyKaryopharm up 23% after Phase 3 SENTRY trial meets first co-primary endpoint
8d ago
KPTI
Karyopharm’s Phase 3 SENTRY trial meets first co-primary endpoint
Premium
The Fly
Karyopharm’s Phase 3 SENTRY trial meets first co-primary endpoint
8d ago
KPTI
Karyopharm announces $30M private placement
Premium
The Fly
Karyopharm announces $30M private placement
8d ago
KPTI
Karyopharm initiated with a Buy at Rodman & Renshaw
PremiumThe Fly
Karyopharm initiated with a Buy at Rodman & Renshaw
23d ago
KPTI
Karyopharm Amends Credit Agreement to Extend Liquidity Runway
PremiumCompany Announcements
Karyopharm Amends Credit Agreement to Extend Liquidity Runway
29d ago
8K
KPTI
Karyopharm Shareholders Approve Major Authorized Share Increase
PremiumCompany Announcements
Karyopharm Shareholders Approve Major Authorized Share Increase
1M ago
8K
KPTI
Buy Rating Reaffirmed on De‑Risked SENTRY Readout and Undervalued Selinexor Cash Flow Potential
PremiumRatings
Buy Rating Reaffirmed on De‑Risked SENTRY Readout and Undervalued Selinexor Cash Flow Potential
1M ago
KPTI
Karyopharm Therapeutics Faces Rising Regulatory and Political Risks Amid Supreme Court Limits on FDA Authority
PremiumCompany AnnouncementsKaryopharm Therapeutics Faces Rising Regulatory and Political Risks Amid Supreme Court Limits on FDA Authority
2M ago
KPTI
Karyopharm Earnings Call: Pivotal Data Amid Cash Squeeze
Premium
Company Announcements
Karyopharm Earnings Call: Pivotal Data Amid Cash Squeeze
2M ago
KPTI
Karyopharm reports Q4 EPS ($5.71) vs. ($3.67) last year
Premium
The Fly
Karyopharm reports Q4 EPS ($5.71) vs. ($3.67) last year
2M ago
KPTI
Karyopharm sees 2026 revenue $130M-$150M, consensus $146.86M
PremiumThe Fly
Karyopharm sees 2026 revenue $130M-$150M, consensus $146.86M
2M ago
KPTI
KPTI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
KPTI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
KPTI
Karyopharm initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Karyopharm initiated with an Overweight at Cantor Fitzgerald
2M ago
KPTI
Karyopharm Issues Preliminary 2025 Financial Results and Outlook
PremiumCompany Announcements
Karyopharm Issues Preliminary 2025 Financial Results and Outlook
3M ago
8K
KPTI
Karyopharm sees FY25 revenue $145M, consensus $147.83M
PremiumThe FlyKaryopharm sees FY25 revenue $145M, consensus $147.83M
3M ago
KPTI
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
5M ago
FIG
TBT
Karyopharm Therapeutics’ Earnings Call: Progress Amid Challenges
Premium
Company Announcements
Karyopharm Therapeutics’ Earnings Call: Progress Amid Challenges
5M ago
KPTI

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >